Health Care Quality, Access, and Evaluation: News and Research on Clinical Trials, Phase III as Topic

MeSH tree: N05.715.360.330.250.250.220

FDA approves Exdensur for severe asthma

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.

page 2 from 2